Table D30. Patient satisfaction outcomes 2

| Author, Year  Trial Name | Patient satisfaction 2 | Description of Timing of Measurement of Outcome | Data source | N | Results |
| --- | --- | --- | --- | --- | --- |
| Katon et al., 199524 NA | % of patients reporting antidepressant meds as helping somewhat to a great deal | baseline, 4 months | self-report | **Major depression group** N=91  **Minor depression group** N=126 | **Major depression group**  G1: 88.1 G2: 63.3 95% CI, NR  p: <0.01  **Minor depression group**  G1: 81.8 G2: 61.4 95% CI, NR  p: <0.02 |
| Katon et al., 199625 NA | % Rating antidepressant medication as helping somewhat to a great deal | 4-month follow up | questionnaire |  | **Major Depression Group** G1: 80% G2: 58.3% p: <0.10  **Minor Depression Group** G1: 94.6% G2: 88.6% p: 0.36 |
| Mann et al., 201034  The Statin Choice | Decisional Conflict Scale--support subscale, with lower scores representing less conflict | Immediately after intervention and control | self-report | G1: NR  G2: NR | G1: 25.2  G2: 29.6  95% CI, NR  p: 0.05 |
| Pearce et al., 200839 Cardiovascular Risk Education and Social Support (CaRESS) Trial | Rating of overall health care | Twice over a 12-month period, at baseline and endpoint | Patient Healthcare Satisfaction Survey | **BL** G1 + G2: 98 G3: 86  **EP** G1 + G2: 71 G3: 67 | **BL** G1 + G2: 9.3 G3: 9.2 95% CI, NR  p (G1 + G2 vs. G3): 0.6931 (unadjusted), NA (adjusted)  **EP** G1 + G2: 8.3 G3: 8.5 95% CI, NR p (G1 + G2 vs. G3): 0.0255 (unadjusted), 0.6709 (adjusted) |
| Powell et al., 199540 NA | Would like to receive more educational videotapes | Once in a randomly selected subset of G1 subjects during the study's 4th month | Mailed survey | G1: 97 G2: NA | **Yes (N (%))**  G1: 66 (68.0%) G2: NA 95% CI, NR p: NR  **No (N (%))**  G1: 16 (16.5%) G2: NA 95% CI, NR p: NR  **No response (N (%))**  G1: 15 (15.5%) G2: NA 95% CI, NR p: NR |
| Solomon et al., 199854  NA  Gourley et al., 199855  NA | Hypertension group: Knowledge dimension- "Helps me understand my illness" (item 2) | One measurement at final visit | Pharmaceutical Care Questionnaire (PCQ)- Likert scale of 1 (strongly agree) to 5 (strongly disagree) | G1: 62  G2: 68 | G1:1.45 (0.59 SD)  G2: 1.84 (0.77 SD)  95% CI, NR  p: 0.002 |
| Weymiller et al., 200762  Statin Choice Randomized Trial  Jones et al., 200963  Statin Choice Randomized Trial | Acceptable clarity of information | Once immediately after the intervention | Self-administered written questionnaire (7-point Likert scale question) | G1: 26 G2: 26 G3: 23 G4: 23  G1: 26 G2: 26 G3: 23 G4: 23 | **N (%) responding 6 or 7 of 7** G1: 19 (73%) G2: 13 (52%) G3: 12 (52%) G4: 12 (52%) 95% CI, NR p: NR  **Odds ratio for decision aid** (G1 & G2) vs. control (G3 & G4) = 1.6  95% CI, 0.8 to 3.2 p: NR  **Mean (95% CI)** G1: 6.0 (5-7) G2: 6.5 (5-7) G3: 6.0 (4-7) G4: 6.0 (4-6) 95% CI, NR p: NR |